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Medication use during pregnancy is challenging due to the occurrence of maternal or fetal toxicities. Atazanavir/ritonavir (ATV/r) has 
hepatotoxic potential hence; use in pregnant patients living with human immunodeficiency virus may cause maternal hepatotoxicity. This 
study assessed the liver profile of ATV/r in pregnant albino rats. Thirty pregnant albino rats randomized into groups were orally treated 
daily with ATV/r (4.28/1.43 mg/kg-34.3/11.4 mg/kg) for 16 days. After treatment, the rats were weighed and sacrificed. Blood samples 
were collected and examined for serum biochemical parameters. Liver samples were weighed and assessed for biochemical and 
histological changes. Body and liver weights were normal (p>0.05) in ATV/r-treated pregnant rats when compared to control. Serum total 
cholesterol, triglyceride, low density lipoprotein cholesterol and blood glucose levels were significantly (p<0.01) elevated whereas high 
density lipoprotein cholesterol level was significantly (p<0.01) decreased in rats treated with ATV/r (34.3/11.4 mg/kg) when compared to 
control. Liver and serum aminotransferases, alkaline phosphatase, gamma-glutamyl transferase, lactate dehydrogenase, total bilirubin, and 
conjugated bilirubin levels were significantly increased in a dose-dependent fashion in rats treated with ATV/r; 8.57/2.86 mg/kg (p<0.05), 
17.1/5.72 mg/kg (p<0.01) and 34.3/11.4 mg/kg (p<0.001) when compared to control. Liver superoxide dismutase, catalase, glutathione 
and glutathione peroxidase levels were significantly decreased whereas malondialdehyde levels were significantly increased in a dose-
dependent fashion in rats treated with ATV/r; 8.57/2.86 mg/kg (p<0.05), 17.1/5.72 mg/kg (p<0.01) and 34.3/11.4 mg/kg (p<0.001) when 
compared to control. Necrotic hepatocytes were observed at higher doses of ATV/r. ATV/r may not be hepatotoxic in pregnant women 
living with HIV at the clinical dose. 
 





Human immunodeficiency (HIV) infection is a leading 
cause of maternal and neonatal morbidity and mortality 
(Abdol-Karim et al., 2010). Pregnancy, whether actual 
or anticipated, has been a critical driver for the 
diagnosis, treatment and care of women living with HIV 
to prevent transmission from mother to child. This 
necessitates the use of highly active antiretroviral 
therapy (HAART) in pregnant women living with HIV 
and neonates exposed to HIV. This strategy has 
drastically reduced mother to child transmission of HIV 
(Coovadia et al., 2007). Most HAART have 
demonstrated favorable safety profiles for mothers and 
infants during trial follow-up (Coovadia et al., 2007). 
However, toxicities have been reported in some quarters 
with growing concern on hepatotoxicity in pregnant 
women (Bera et al., 2012). The use of medication during 
pregnancy has been a serious clinical challenge in terms 
of maternal and fetal safety due to physiological changes 
and complications that do arise during pregnancy. 
Hepatitis, intrahepatic cholestasis, and acute fatty liver, 
are some complications that may occur during 
pregnancy (Hammoud et al., 2014). Also, pregnancy 
could increase the incidence of treatment related adverse 
effect including hepatotoxicity (Joy et al., 2015; Clark, 
2015) and has a significant impact on the efficacy and 
safety of a drug (Abduljalil et al., 2012). 
Atazanavir/ritonavir (ATV/r) is use as a component of 
HAART in the management of HIV (Mandelbrot et al., 
2011). Its use in HIV management has decreased 
mortality associated with HIV. It has a high genetic 
barrier to resistance, favorable adherence profile and 
low effects on lipids and glucose metabolism 
(Achenbach et al., 2011). However, it has been 
associated with hyperglycemia, alterations in cardiac 
conduction and renal toxicity (Clayden, 2009; Conradie 
et al., 2011; Hamada et al., 2012). Furthermore, 
elevations in serum liver enzymes and indirect 
hyperbilirubinemia have been reported hence, use in 
pregnant women living with HIV raises toxicological 
concern such as hepatotoxicity (Eholié et al., 2013). 
This study assessed the liver profile of ATV/r in a 
pregnant albino rat model. 
 
 
MATERIAL AND METHODS 
 
Animal and Drugs 
Pregnant albino rats (200g-250g) used for this study 
were obtained from the animal house of the Department 
of Pharmacology and Toxicology, Madonna University, 
Nigeria. The rats were housed under room temperature 
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with a 12:12 light: dark cycle. The rats were randomized 
into 6 rats per cage according to their weights and had 
free access to diet and water. ATV/r used for this study 
was manufactured by Mylan laboratories limited India. 
The doses of ATV/r (4.28/1.43, 8.57/2.86, 17.1/5.72, 
and 34.3/11.4 mg/kg) used for this study represent 
clinical dose, 2, 4, and 8, times the clinical dose 
respectively (von Hentig et al., 2007).  
 
Experimental protocol 
The reproductive status and estrous period of the rats 
were determined by obtaining their virginal smears. 
After two complete regular cycles, timed mating of 
female rats was done on the night of the pro-estrous (N) 
phase of the cycle. In the morning following mating, 
vaginal smears were taken again. The presence of 
spermatozoa and squamus cells in the smear confirmed 
mating and fertilization of ovule. The sperm – positive 
morning was thus designated day 0 of pregnancy. Thirty 
pregnant albino rats used were weighed and divided into 
five groups labeled A–E of six rats each. Group A 
(Control) orally received normal saline (0.2mL) whereas 
groups B-E orally received ATV/r (4.28/1.43 mg/kg, 
8.57/2.86 mg/kg, 17.1/5.72 mg/kg and 34.3/11.4 mg/kg) 
daily for 16 days respectively. 
 
Collection of samples and biochemical analyses 
The rats were sacrificed on day 17 after exposure to 
inhalational diethyl ether.  Blood samples were collected 
and centrifuged at 1200g for 15 minutes and sera 
extracted. Sera were analyzed for biochemical 
parameters. Liver samples were collected, weighed and 
washed in a cold 1.15 % KCl solution and homogenized 
in 0.1 M Tris-HCl buffer, pH 7.4. The homogenates 
were centrifuged at 1200 g speed for 15 minutes and the 
supernatants were collected and evaluated for 
biochemical parameters. Alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP), gamma-glutamyl transferase 
(GGT), lactate dehydrogenase (LDH), total bilirubin 
(TB), conjugated bilirubin (CB), triglyceride (TG), total 
cholesterol (TC), and high density lipoprotein 
cholesterol (HDL-C) were evaluated using commercial 
test kits (Randox Diagnostics, Crumlin, UK). Blood 
glucose (G) was estimated with the aid of a glucometer 
whereas low density lipoprotein cholesterol (LDL-C) 
was estimated as reported by Friedewald et al. (1972). 
Liver superoxide dismutase (SOD) was determined as 
described by Sun and Zigma, (1978). Catalase (CAT) 
was assayed according to Aebi, (1984). Glutathione 
(GSH) was estimated according to Sedlak and Lindsay, 
(1968). Malondialdehyde (MDA) was determined as 
reported by Buege and Aust, (1978). The method of 
Rotruck et al. (1973) was used for the evaluation of 
glutathione peroxidase (GPx) whereas total protein was 
evaluated according to Gonall et al. (1949). 
 
Histological examination of the liver 
Liver samples were collected, cleaned and weighed. 
Liver samples were fixed in10% buffered neutral 
formalin for 24h. Liver samples were dehydrated in 
increasing ethanol concentrations and mounted in 
paraffin block. Paraffin sections (3-5 μm) were 
prepared, deperaffinized and stained with hematoxylin 
and eosin dye (H&E). Stained sections were examined 
using a light microscope for histological changes. 
 
Statistical analysis 
Results are expressed as mean ± SEM and were 
evaluated using one way analysis of variance (ANOVA) 
followed by Dunnett’s post hoc tests. Results were 





The body and liver weights of pregnant rats treated with 
ATV/r were not significantly (p>0.05) different when 
compared to control (Table 1).  Significant increases in a 
dose-dependent fashion occurred in the liver and serum 
AST, ALT, ALP, GGT, LDH, TB and CB levels in rats 
treated with ATV/r (Tables 2 and 3). The increases in 
the levels of the aforementioned parameters were not 
significant (p>0.05) at the clinical dose (4.28/1.43 
mg/kg), but were significant at 8.57/2.86 mg/kg 
(p<0.05), 17.1/5.72 mg/kg (p<0.01) and 34.3/11.4mg/kg 
(p<0.001) when compared to control (Tables 2 and 3). 
Serum TG, TC, LDL-C and blood G levels were 
significantly (p<0.01) increased whereas serum HDL-C 
level was significantly (p<0.01) decreased in pregnant 
rats treated with ATV/r (34.3/11.4 mg/kg) when 
compared to control (Table 4). Treatment with ATV/r 
produced decreases in liver SOD, CAT, GSH and GPx 
levels with increases in MDA levels in a dose-dependent 
fashion (Table 5). The effects on liver SOD, CAT, GSH, 
GPx and MDA levels were not significant (p>0.05) at 
the clinical dose (4.28/1.43 mg/kg), but were significant 
at 8.57/2.86 mg/kg (p<0.05), 17.1/5.72 mg/kg (p<0.01) 
and 34.3/11.4 mg/kg (p<0.001) when compared to 
control (Table 5). The liver of control rat showed normal 
hepatocytes (Figure A). The liver of rats treated with 
ATV/r (4.28/1.43 mg/kg) showed inflammatory cell 
infiltration (Figure B). In contrast, the liver of rats 
treated with ATV/r; 8.57/2.86 mg/kg, 17.1/5.74 mg/kg 
and 34.3/11.4 mg/kg showed hepatocyte necroses 
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Table 1. Effects of atazanavir/ritonavir on body and liver weights of pregnant albino rats. 
 





















TV/r =Atazanavir/ritonavir, Data are expressed as mean± SEM.  n=6 
 
 
Table 2. Effect of atazanavir/ritonavir on serum liver function parameters of pregnant albino rats. 
 
Group AST(U/L) ALT(U/L) ALP(U/L) GGT(U/L) LDH(U/L) CB(g/dL) TB(g/dL) 
A 45.5±3.99 34.2±2.15 47.3±3.56 48.5±3.12 0.73±0.04 4.50±0.18 8.54±0.71 
B 50.3±3.46 38.8±2.25 51.9±4.06 52.1±4.00 0.80±0.02 4.87±0.25 9.01±0.36 
C 66.7±5.00a 45.8±4.70a 70.4±5.36a 78.2±5.31a 1.31±0.19a 6.44±1.22a 12.7±1.11a 
D 96.3±7.87b 63.3±2.62b 99.4±8.66b 121.1±10.6b 1.90±0.12b 8.95±1.06b 15.5±1.40b 
E 140.6±10.3c 128.8±7.00c 155.3±10.3c 180.4±12.5c 2.60±0.52c 13.3±1.01c 23.5±2.22c 
ATV/r: Atazanavir/ritonavir, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, AST: Aspartate aminotransferase, GGT: Gamma-glutamyl 
transferase, LDH: Lactate dehydrogenase, CB: Conjugated bilirubin, TB: Total bilirubin. Data are expressed as mean± SEM.  n=6. a Differ significantly 
(p<0.05) when compared to control, b Differ significantly (p<0.01) when compared to control, c Differ significantly (p<0.001) when compared to control.  
 
 
Table 3. Effect of atazanavir/ritonavir on some biochemical parameters in the liver tissue of pregnant albino rats. 
 
Group ALT(U/L) AST(U/L) ALP(U/L) GGT(U/L) LDH(U/L) 
A 185.0±15.5 173.8±14.1 187.2±15.34 192.5±12.2 3.25±0.18 
B 200.5±19.1 211.2±16.1 201.4±11.4 224.7±16.2 3.76±0.12 
C 321.3±20.2a 338.2±22.2a 351.0±18.4a 330.1±20.6a 4.84±0.85a 
D 463.8±22.6b 548.1±18.7b 474.2±19.0b 580.1±17.1b 6.95±0.32b 
E 695.2±27.4c 789.2±20.6c 690.0±21.9c 768.8±22.8c 9.97±0.71c 
ATV/r: Atazanavir/ritonavir, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, AST: Aspartate aminotransferase, GGT: Gamma-glutamyl 
transferase, LDH: Lactate dehydrogenase. Data are expressed as mean± SEM.  n=6. a Differ significantly (p<0.05) when compared to control, b Differ 
significantly (p<0.01) when compared to control, c Differ significantly (p<0.001) when compared to control.  
 
 
Table 4. Effect of atazanavir/ritonavir on lipid profile of pregnant albino rats. 
 
Group G (mg/dL) TG(mg/dL) TC(mg/dL) HDL-C (mg/dL) LDL-C (mg/dL) 
A 95.0±6.41 70.5±6.78 110.1±12.8 30.7±3.44 65.7±6.00 
B 92.0±9.00 74.9±6.70 112.0±13.6 32.6±2.61 64.5±6.42 
C 89.3±6.42 73.2±7.53 109.8±12.0 32.5±3.72 63.8±5.11 
D 100.9±9.19 81.1±7.56 110.3±11.1 29.4±2.63 65.7±7.62 
E 152.0±8.00a 132.7±9.21a 161.0±14.1a 21.3±2.10a 113.4±8.32a 
Data are express as mean± SEM.  n=6 G: Glucose, TG: Triglyceride TC: Total cholesterol HDL-C: High density lipoprotein cholesterol, LDL-C: Low 
density lipoprotein cholesterol. a Significant (p<0.01) when compared to control 
 
 













A 0.32±0.05 16.2±2.09 26.4±3.77 8.97±0.15 9.44±0.12 
B 0.36±0.01 14.6±1.04 23.6±2.87 8.25±0.70 9.10±0.12 
C 0.50±0.08a 10.4±1.06a 15.5±3.05a 5.88±0.54a 7.42±0.34a 
D 0.68±0.03b 7.06±1.15b 10 .6±1.37b 3.10±0.79b 5.02±0.44b 
E 0.98±0.01c 3.16±0.27c 20.5±3.07c 1.06±0.58c 2.11±0.53c 
ATV/r: Atazanavir/ritonavir, MDA: Malondialdehyde, CAT: Catalase, GSH: Glutathione, SOD: Superoxide dismutase,  GPx: Glutathione peroxidase. 
Data are expressed as mean± SEM.  n=6. a Differ significantly (p<0.05) when compared to control, b Differ significantly  (p<0.01) when compared to 










    
  
 
Figure 1. Fig A: Liver of control pregnant albino rat showing normal hepatocytes. Fig B: Liver of pregnant albino rat treated with ATV/r (4.28/1.43 
mg/kg) showing inflammatory cell infiltration. Fig C: Liver of pregnant albino rat treated with ATV/r (8.57/2.86 mg/kg) showing hepatocyte necrosis. Fig 
D: Liver of pregnant albino rat treated with ATV/r (17.1/5.74 mg/kg) showing hepatocyte necrosis. Fig E: Liver of pregnant albino rat treated with ATV/r 
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Drug-induced liver injury is a potential complication of 
nearly every prescribed drug and many fatal and near-
fatal drug reactions occurred each year (Lee, 1995). 
Pregnancy-related liver disease is the most frequent 
cause of liver dysfunction in pregnancy and provides a 
real threat to fetal and maternal survival (Joshi, 2010) 
and could be aggravated by some medications (Eyal et 
al., 2010). This makes the provision of antiretroviral 
therapy during pregnancy a serious clinical challenge 
due to the possible occurrence of hepatotoxicity. The 
present study evaluated the liver profile of ATV/r in 
pregnant albino rats. The evaluation of organ weight in 
toxicology studies is an integral component in the 
assessments of pharmaceuticals, chemicals, and medical 
devices (Wooley, 2003). This study did not observe 
significant changes in the body and liver weights of 
ATV/r-treated pregnant rats. Serum TG, TC, LDL-C, 
HDL-C and blood G levels are yardsticks for 
hyperlipidemia and hyperglycemia caused by drugs 
(Ehigiator and Adikwu, 2019). This study, observed 
elevated levels of serum TG, TC, LDLC and blood G 
with decreased HDLC level at the highest ATV/r dose. 
These observations are possible signs of hyperlidemia 
and hyperglycemia (Ehigiator and Adikwu, 2019). The 
serum levels of ALT, AST, ALP, LDH and GGT are 
effective clinical tools for the assessment of liver status 
(Navarro and Senior, 2006). AST is found in 
mitochondria and cytosol of hepatocytes, ALT is 
localized to the cytosol whereas ALP is found on the 
sinusoidal surface of hepatocytes (Rosen and Keefe, 
2000).  LDH is a cytoplasmic marker enzyme whereas 
GGT is a membrane bound enzyme. Higher serum 
activities of the aforementioned parameters are often 
associated with hepatic damage (Kim et al., 2001). This 
study observed elevations in the serum and liver levels 
of ALT, AST, ALP, LDH and GGT in a dose-dependent 
fashion in ATV/r-treated pregnant rats. This observation 
may be due to the damage of liver hepatocyte membrane 
leading to the release of the aforementioned parameters 
into the blood. The measurement of bilirubin is a very 
sensitive test to substantiate the functional integrity of 
the liver and severity of necrosis (Singh et al., 1989). 
This study observed elevations in serum CB and TB 
levels in a dose-dependent fashion in ATV/r-treated 
pregnant rats. This may be due to decreased disposal of 
bilirubin by the liver or the blockade of the excretory 
duct of the liver. 
Reactive oxygen species (ROS) could be toxic or 
beneficial for cellular functions. The toxic effects of 
ROS can occur as a result of excess activity due to 
overload or accumulation leading to oxidative stress 
(OS). OS plays a major part in the development of 
chronic and degenerative diseases. Antioxidants such as 
SOD, CAT, GSH and GPx are inhibitors of OS even at 
relatively low concentrations, but their functions can be 
incapacitated by insurmountable activities of ROS 
(Sultan, 2014). In this study, hepatic SOD, CAT, GSH 
and GPx levels were depleted in a dose-dependent 
fashion in ATV/r- treated pregnant rats. 
Malondialdehyde (MDA) is a highly reactive three 
carbon dialdehyde produced as a byproduct of 
polyunsaturated fatty acid oxidation and during 
arachidonic acid metabolism for the synthesis of 
prostaglandins. The monitoring of MDA level in 
biological systems has been an important indicator of 
lipid peroxidation (LPO) in-vitro and in-vivo (Janero, 
1990). This study observed increases in hepatic MDA 
levels in a dose-dependent fashion in ATV/r-treated 
pregnant rats which indicate hepatic LPO.  LPO is the 
oxidative destruction of lipids containing carbon-carbon 
double bond resulting in lipid peroxyl radicals and hydro 
peroxides production. Lipid peroxyl radicals and 
hydroperoxides can stimulate alterations in cell signal 
transduction and functions leading to cell necrosis and 
apoptosis, which may facilitate the development of 
various pathological states (Yin et al., 2011).  
Liver histological examination contributes to 
diagnostic accuracy in drug-induced liver damage and 
remains a valuable tool for the evaluation of drug-
induced liver damage. As a clinical test, it provides more 
information about the state of the liver than any other 
single assay (Kleiner, 2014). Histopathological 
examination of the liver of ATV/r-treated pregnant rats 
showed necrotic hepatocytes at higher doses. The 
observed necrotic hepatocytes correlate with changes in 
evaluated biochemical parameters. Hepatic necroses 
observed in ATV/r-treated rats could be attributed to 
OS, because OS as a consequence of ROS production 
can cause progressive modification or degradation of 
biomolecules such as DNA, proteins, lipids and 
carbohydrates. This can lead to loss of cell function, cell 






The use of ATV/r in pregnant women living with HIV 
may not cause hepatotoxicity at the clinical dose. 
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